Target intelligence / Profile preview

Cyclooxygenase (COX) enzymes in colonic epithelial cells (COX (specifically COX-1 and COX-2))

Target
COX (specifically COX-1 and COX-2)
Molecular classification
Enzyme, Oxidoreductase, Prostaglandin synthase family
01

Overview

The cyclooxygenase pathway in colonic epithelial cells involves two key enzymes—cyclooxygenase 1 (COX‑1) and cyclooxygenase 2 (COX‑2)—that catalyze the conversion of arachidonic acid into prostaglandins. These lipid mediators play essential roles in regulating inflammation, maintaining mucosal integrity, and modulating immune responses. While COX‑1 is constitutively expressed at stable levels throughout normal colon epithelium, COX‑2 expression is typically absent under normal conditions but becomes highly induced during inflammatory states such as inflammatory bowel disease. The upregulation of COX‑2 has been implicated both in chronic inflammation and tumorigenesis within the colon. Both isoforms are clinically relevant drug targets for anti-inflammatory therapies; however, their inhibition carries distinct safety profiles related to gastrointestinal protection and cardiovascular health[1].

Other names
Prostaglandin-endoperoxide synthasesPTGS1 (for COX-1)PTGS2 (for COX-2)Cyclooxygenases
02

Mechanism of action

Inhibition of prostaglandin synthesis by blocking enzymatic activity of COX‑1/COX‑2 Reduction of inflammation and pain via decreased prostaglandin production

03

Biological functions

Prostaglandin synthesisInflammatory response regulationMucosal protection in the gastrointestinal tract
04

Disease associations

InflammationCancer (notably colorectal cancer)Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis
05

Safety considerations

Gastrointestinal toxicity/ulceration with non-selective NSAIDs due to inhibition of protective prostaglandins from COX‑1Increased cardiovascular risk with selective COX‑2 inhibitors
06

Interacting drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs; e.g., aspirin, ibuprofen, naproxen)

1 more in the full profile.

07

Biomarkers

Expression levels of COX‑2 protein in inflamed or neoplastic tissue can serve as a biomarker for inflammation or cancer risk/progression

Beyond the preview

Go deeper on Cyclooxygenase (COX) enzymes in colonic epithelial cells (COX (specifically COX-1 and COX-2)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclooxygenase (COX) enzymes in colonic epithelial cells (COX (specifically COX-1 and COX-2)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call